Patents Assigned to Aventis Pharma Deutschland GmbH
  • Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
    Publication number: 20050101599
    Abstract: The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.
    Type: Application
    Filed: November 2, 2004
    Publication date: May 12, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Zeiher, Stefanie Dimmeler, Christopher Heeschen, Hartmut Ruetten
  • Method and device for the quantitative analysis of solutions and dispersions by means of near infrared spectroscopy
    Publication number: 20050092941
    Abstract: The present invention relates to a method for quantifying the composition of a product, with the following steps: irradiating the product with a radiation source in the near infrared range; receiving radiation which is reflected by or transmitted through the product, and providing an output signal corresponding to the intensity of the radiation received at a number of different wavelengths; determining whether or not the product lies within predetermined integrity criteria on the basis of the output signal using a mathematical method, wherein the product contains a solution or homogeneous dispersion, and the content of at least one substance contained in the dispersion or solution is quantitatively determined on the basis of the output signal. The present invention also relates to an apparatus for carrying out this method.
    Type: Application
    Filed: June 4, 2004
    Publication date: May 5, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Christian-Peter Christiansen, Hans-Joachim Ploss, Richard Mertens, Heino Prinz
  • Medicinal targeted local lipolysis
    Publication number: 20050089555
    Abstract: Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue.
    Type: Application
    Filed: October 21, 2004
    Publication date: April 28, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Peter Boderke, Rainer Pooth, Juergen Sandow, Matthias Gossel, Karl-Heinz Nietsch, Gerhard Sattler, Gerhard Vogel
  • Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
    Patent number: 6884812
    Abstract: Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: April 26, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heiner Glombik, Eugen Falk, Wendelin Frick, Stefanie Keil, Hans-Ludwig Schäfer, Lothar Schwink, Wolfgang Wendler
  • Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
    Publication number: 20050085483
    Abstract: Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.
    Type: Application
    Filed: February 13, 2004
    Publication date: April 21, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Petra Stahl, Pavel Safar, James Spoonamore, Martin Smrcina, Joseph Klein, Gregory Merriman, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
  • Crystals of insulin analogs and processes for their preparation
    Publication number: 20050085621
    Abstract: The invention relates to crystals of an insulin analog in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring neutral or acidic amino acid residue, where phenylalanine (Phe) in position B1 of the B chain can optionally be absent, the crystals being present in the space group R3 (No. 146) with the cell axes A=81.5 ?±1 ? and C=33.3 ?±1 ?, their preparation and use, and a pharmaceutical composition comprising these crystals.
    Type: Application
    Filed: October 29, 2003
    Publication date: April 21, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventor: Harald Berchtold
  • Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
    Patent number: 6881735
    Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: April 19, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Use of C2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
    Publication number: 20050080057
    Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of of C2-substituted indan-1-ol systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in the methods of the embodiments of the invention include compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts.
    Type: Application
    Filed: December 7, 2004
    Publication date: April 14, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Method of purifying preproinsulin
    Publication number: 20050080000
    Abstract: The invention relates to a method for the chromatographic purification of preproinsulins, in which higher molecular weight substances are removed from an aqueous solution of preproinsulin by a first chromatography on an anion exchanger in flow-through mode and a subsequent second chromatography on a cation exchanger in adsorption mode, and to a method for preparing insulins, which includes the method for preparing preproinsulins.
    Type: Application
    Filed: August 1, 2003
    Publication date: April 14, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Horst Thurow, Hans Blumenstock, Chantalle Havenith
  • Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
    Publication number: 20050080127
    Abstract: The present invention is directed to a compound of formula (I), or a stereoisomer or a mixture of stereoisomer thereof in any ratio, or its physiologically tolerable salt, which is useful as an inhibitor of matrix metalloproteinase. The present invention is also directed to a pharmaceutical preparation comprising a pharmaceutically effective amount of at least one compound of formula (I); processes for their preparation; the use of a compound of formula (I) having activity as an matrix metalloproteinase inhibitor; and for the prophylaxis and therapy of disease states that involve an increase in the activity of matrix metalloproteinase.
    Type: Application
    Filed: September 27, 2004
    Publication date: April 14, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Manfred Schudok, Hans Matter, Armin Hofmeister
  • Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them
    Patent number: 6878748
    Abstract: Fluorinated cycloalkyl-derivatized benzoylguanidines of formula I are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also preventively inhibit the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: April 12, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventor: Heinz-Werner Kleemann
  • Antisense oligonucleotides against tenascin for treating vitiligo
    Patent number: 6878547
    Abstract: The invention relates to specific, optionally modified oligonucleotides with a length of up to 17 nucleotides. Said oligonucleotides correspond to segments of tenascin-coding sequences or can bind to these sequences. The invention also relates to the production and use of the oligonucleotides, for example for the specific inhibition of the expression of tenascin and for producing medicaments used to treat vitiligo.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: April 12, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Anuschirwan Peyman, Eugen Uhlmann, Caroline Weiser
  • Substituted thienoimidazoles useful for disease treatment and prevention
    Publication number: 20050075385
    Abstract: Substituted thienoimidazoles with a backbone structure of formula I or II: These substituted thienoimidazoles are useful in prevention or treatment of various disorders, including respiratory disorders.
    Type: Application
    Filed: August 25, 2004
    Publication date: April 7, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Hans-Jochen Lang, Uwe Heinelt, Klaus Wirth, Thomas Licher
  • Use of Saccharomyces cerevisiae Erg4 mutants for expressing mammalian glucose transporters
    Publication number: 20050074845
    Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.
    Type: Application
    Filed: September 10, 2003
    Publication date: April 7, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Guenter Mueller, Silke Dlugai, Doerthe Voss, Eckhard Boles
  • Preparations for topical administration of substances having antiandrogenic activity
    Patent number: 6875438
    Abstract: A preparation comprising at least one form of lipid nanoparticles or a nanoemulsion comprising at least one compound of the formula I and/or one stereoisomeric form of the compound of the formula I and/or one physiologically tolerated salt of the compound of the formula I, in which R1 is —(C5-C17)-alkyl or —(C5-C17)-alkenyl, is suitable for the treatment of androgenic alopecia, of hirsutism, that is to say to prevent unwanted hair growth, and for the treatment of seborrhea and acne and can furthermore be employed in cosmetics.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: April 5, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Karl Theodor Kraemer, Karl-Heinz Nietsch, Rainer Pooth, Uwe Muenster, Wolfgang Mehnert, Monika Schaefer-Korting
  • Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
    Publication number: 20050070533
    Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for lowering the blood glucose and for the prevention and treatment of diabetes.
    Type: Application
    Filed: July 27, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller
  • Substituted benzoylureido-o-benzoylamides, process for their preparation and their use
    Publication number: 20050065142
    Abstract: The invention relates to substituted benzoylureido-o-benzoylamides and to their physiologically tolerated salts and physiologically functional derivatives. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
    Type: Application
    Filed: July 27, 2004
    Publication date: March 24, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Dieter Kadereit, Elisabeth Defossa, Karl Schoenafinger, Thomas Klabunde, Andreas Herling
  • Methods of using and preparing thiolutin dioxide
    Publication number: 20050059725
    Abstract: The present invention relates to the use of thiolutin dioxide and its derivatives in the manufacture of a medicament. Such medicaments are useful, for example, in the treatment of CNS disorders. The present invention also relates to a process for the production of thiolutin dioxide and its derivatives by fermentation of microorganisms, such as the microorganism Nocardiopsis species ST 100692 (DSM 13834).
    Type: Application
    Filed: October 26, 2004
    Publication date: March 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Claudia Eder, Michael Kurz, Joachim Wink
  • High-throughput-assay with high sensitivity for measuring of the activity of beta-adrenergic receptor kinase and for determining the impact of test substances on such activity
    Publication number: 20050059098
    Abstract: The invention refers to an assay for determining the activity of a G-Protein-Coupled Receptor specific protein kinase by means of an amplified luminescent proximity homogenous assay.
    Type: Application
    Filed: August 31, 2004
    Publication date: March 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Aimo Kannt, Antje Pommereau, Harald Thuering, Jochen Huber, Martin Oppermann
  • Medical device for injecting fluid medicaments
    Patent number: D503477
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: March 29, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Miles Hawley, Stephens Sayers